In the single-arm phase II HAWK study, durvalumab has been evaluated as a monotherapy in the treatment of immunotherapy-naïve R/M HNSCC with high PD-L1 protein expression (≥25% of tumor cells). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.